Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 20/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20901306 | 0.82 | CHRM1 (0.48) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL15618571 | 0.82 | CHRM1 (0.68) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL20901307 | 0.80 | CHRM1 (0.48) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL15623191 | 0.79 | CHRM1 (0.48) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL18922668 | 0.79 | CHRM1 (0.48) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL15618702 | 0.79 | CHRM1 (0.70) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL15630183 | 0.78 | CHRM1 (0.47) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL21597926 | 0.74 | CHRM1 (0.63) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL20901247 | 0.74 | CHRM1 (0.41) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL22472944 | 0.72 | CHRM1 (0.67) | CHRM1CHRM5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM5 3/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.